Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the UK / NCT05077124
Active, not recruiting Observational

Safe and Timely Antithrombotic Removal (STAR) Registry

NCT05077124 · tracked via the Priya Life Science UK tracker
Sponsor
CytoSorbents, Inc
Phase
Observational
Started
2021-09-30
Last updated
2026-10-21

Condition(s) studied

Hemorrhage, SurgicalHemorrhage PostoperativeBlood Loss, SurgicalBlood Loss, Postoperative

Investigational drug(s) / intervention(s)

CytoSorb

CytoSorb: Sorbent hemoperfusion system

Study summary

This registry will capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb for the removal of antithrombotic agents.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * CytoSorb utilization for antithrombotic removal * Informed consent for prospective registry participation Exclusion Criteria: • Use of CytoSorb for purpose other than antithrombotic removal

Primary outcome measure(s)

  • Bleeding complications including requirements for transfusions and other blood products — Assessed until postoperative day (POD) 3, date of ICU discharge, or date of death, whatever comes first; on average 3 days

Trial sites (29)

FacilityCityRegionStatus
Universitätsklinikum Graz Graz Austria
Medizinische Universität Innsbruck Innsbruck Austria
Medical University of Vienna Vienna Austria
Centre Hospitalier Universitaire de Liège Liège Belgium
OLV ziekenhuis Aalst VZW Aalst Belgium
Cliniques Universitaires Saint-Luc Brussels Belgium
University Hospital Ghent Ghent Belgium
Evangelisches Herzzentrum Coswig Coswig Germany
Herzchirurgische Klinik Erlangen Erlangen Germany
Universitätsklinikum Essen Essen Germany
Asklepios Kliniken Hamburg GmbH Hamburg Germany
Medizinische Hochschule Hannover Hanover Germany
Universitätsklinikum Heidelberg - Klinik für Herzchirurgie Heidelberg Germany
Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Herz- und Gefäßchirurgie Kiel Germany
Herzzentrum Leipzig and Helios Health Institute GmbH Leipzig Leipzig Germany
Artemed Klinikum München Süd GmbH & Co. KG Munich Germany
LMU Klinikum Großhadern Munich Germany
Deutsches Herzzentrum München München Germany
Klinikum Nürnberg Nuremberg Germany
Klinikum Oldenburg AöR Oldenburg Germany
Krankenhaus der Barmherzigen Brüder Trier Trier Germany
Universitätsklinikum Ulm Ulm Germany
Skåne University Hospital Lund Lund Sweden
Hôpitaux Universitaires Genève Geneva Switzerland
Stadtspital Zürich Clinic for Cardiac Surgery Zurich Switzerland
Universitätsspital Zürich Zurich Switzerland
Blackpool Teaching Hospitals NHS Foundation Trust/ Blackpool Victoria Hospital Blackpool United Kingdom
Royal Brompton & Harefield Clinical Group (part of Guy's and St Thomas' NHS Foundation TRUST) London United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust Sheffield United Kingdom

Other trials for the same condition

Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05077124 on ClinicalTrials.gov ↗ ← All trials in the UK